- Up to 120 patients with COVID-19 symptoms will be randomized in total
- The recruitment of patients in several European countries progresses swiftly
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, announced today that more than 50% of the number of patients that were planned to be enclosed, have now been enrolled in the Phase II study in COVID-19. The objective of the study is to determine whether the anti-inflammatory effect of MP1032 can slow the spread of the virus in recently hospitalized patients with moderate to severe coronavirus disease and alleviate COVID-19 symptoms.
MetrioPharm's Chief Scientific Officer (CSO) Dr. Wolfgang Brysch commented, "Patient enrollment in this international study is progressing steadily. The set schedule has been met so far and we are optimistic to be able to conduct the study as planned. My sincere appreciation goes to the clinical teams on site in the respective hospitals, who are managing this trial in COVID-19 with great, often personal, commitment in the face of high, regular workloads that this pandemic causes."
The study aims to recruit 120 patients in an early stage of hospitalization. Approximately 80 patients will receive 300 mg of MP1032 twice a day, plus standard of care, and about 40 patients will receive placebo plus standard of care. The trial is being conducted so far in Romania, Hungary, Spain, Bulgaria and Italy. In addition to confirming the safety of MP1032, the primary efficacy endpoint will be the percentage of participants with improved disease symptoms at Day 14, while undergoing treatment with MP1032. First topline data are expected as of H2 2022.
MetrioPharms Chief Executive Officer (CEO) Thomas Christély stated, "I am pleased with the rapid enrollment of patients in our current, Phase II study to date. Among other things, I expect this study to provide further evidence that MetrioPharm's lead compound MP1032 can effectively stop oxidative stress in indications caused by inflammatory processes. Oxidative stress is a key mechanism in acute and chronic inflammatory diseases. Worldwide, more than half of all deaths are caused by chronic inflammatory diseases, and inflammatory processes also appear to play a critical role in severe covid progression."
About the European Commission funding
MetrioPharm's Phase II study in COVID-19 is funded by the European Commission under the HERA Incubator. This funding program was launched in April 2021 to support urgently needed research and development to combat the corona virus and its variant across Europe. MetrioPharm's iMPact project is part of a broad range of European Commission research and innovation activities to combat the corona virus.nThe iMPact project was nominated for European Commission funding in July 2021, and the grant agreement was signed in November 2021.